Mycoplasma pneumoniae-related extra-pulmonary diseases and antimicrobial therapy

Система будет остановлена для регулярного обслуживания. Пожалуйста, сохраните рабочие данные и выйдите из системы.

dc.contributor.author	Poddighe, Dimitri
dc.date.accessioned	2020-05-11T07:51:04Z
dc.date.available	2020-05-11T07:51:04Z
dc.date.issued	2019-05-19
dc.identifier.citation	Poddighe, D. (2020). Mycoplasma pneumoniae-related extra-pulmonary diseases and antimicrobial therapy. Journal of Microbiology, Immunology and Infection, 53(1), 188-189.	en_US
dc.identifier.uri	https://doi.org/10.1016/j.jmii.2019.04.011
dc.identifier.uri	http://nur.nu.edu.kz/handle/123456789/4631
dc.description.abstract	AbstractThe findings by Yang-TI et al. suggested that macrolide-resistance and/or delayed appropriate antimicrobial treatment may contribute to the development of mycoplasma pneumoniae-related extra-pulmonary diseases in children. Indeed, these conditions can have variable clinical expression and severity and may arise in immunologically predisposed children after recurrent/persistent exposure to mycoplasma pneumonia. Copyright 2019, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/	en_US
dc.language.iso	en	en_US
dc.publisher	Elsevier	en_US
dc.rights	Attribution-NonCommercial-ShareAlike 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/3.0/us/	*
dc.subject	Research Subject Categories::MEDICINE	en_US
dc.title	Mycoplasma pneumoniae-related extra-pulmonary diseases and antimicrobial therapy	en_US
dc.type	Article	en_US
workflow.import.source	science